92 related articles for article (PubMed ID: 16197656)
1. Olopatadine: a drug for allergic conjunctivitis targeting the mast cell.
Leonardi A; Quintieri L
Expert Opin Pharmacother; 2010 Apr; 11(6):969-81. PubMed ID: 20307221
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial.
Avunduk AM; Tekelioglu Y; Turk A; Akyol N
Clin Ther; 2005 Sep; 27(9):1392-402. PubMed ID: 16291412
[TBL] [Abstract][Full Text] [Related]
3. Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis.
Castillo M; Scott NW; Mustafa MZ; Mustafa MS; Azuara-Blanco A
Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD009566. PubMed ID: 26028608
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases.
Sharif NA; Xu SX; Miller ST; Gamache DA; Yanni JM
J Pharmacol Exp Ther; 1996 Sep; 278(3):1252-61. PubMed ID: 8819509
[TBL] [Abstract][Full Text] [Related]
5. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent.
Yanni JM; Stephens DJ; Miller ST; Weimer LK; Graff G; Parnell D; Lang LS; Spellman JM; Brady MT; Gamache DA
J Ocul Pharmacol Ther; 1996; 12(4):389-400. PubMed ID: 8951675
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive review of olopatadine: the molecule and its clinical entities.
Kaliner MA; Oppenheimer J; Farrar JR
Allergy Asthma Proc; 2010; 31(2):112-9. PubMed ID: 20406593
[TBL] [Abstract][Full Text] [Related]
7. Olopatadine (AL-4943A): ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis.
Sharif NA; Xu SX; Yanni JM
J Ocul Pharmacol Ther; 1996; 12(4):401-7. PubMed ID: 8951676
[TBL] [Abstract][Full Text] [Related]
8. Olopatadine hydrochloride ophthalmic solution for the treatment of allergic conjunctivitis.
Gonzalez-Estrada A; Reddy K; Dimov V; Eidelman F
Expert Opin Pharmacother; 2017 Aug; 18(11):1137-1143. PubMed ID: 28656804
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial.
Borazan M; Karalezli A; Akova YA; Akman A; Kiyici H; Erbek SS
Acta Ophthalmol; 2009 Aug; 87(5):549-54. PubMed ID: 18631332
[TBL] [Abstract][Full Text] [Related]
10. The effectiveness of olopatadine hydrochloride eye drops for allergic conjunctivitis: Protocol for a systematic review.
Zi Y; Deng Y; Ji M; Qin Y; Nong L; Liu Z; Jin M
Medicine (Baltimore); 2020 Feb; 99(7):e18618. PubMed ID: 32049778
[TBL] [Abstract][Full Text] [Related]
11. Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis.
Dudeja L; Janakiraman A; Dudeja I; Sane K; Babu M
Indian J Ophthalmol; 2019 Sep; 67(9):1400-1404. PubMed ID: 31436181
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye.
Mah FS; O'Brien T; Kim T; Torkildsen G
Curr Med Res Opin; 2008 Feb; 24(2):441-7. PubMed ID: 18167176
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge.
Abelson MB; Spangler DL; Epstein AB; Mah FS; Crampton HJ
Curr Eye Res; 2007 Dec; 32(12):1017-22. PubMed ID: 18085465
[TBL] [Abstract][Full Text] [Related]
14. Topical antihistamines, mast cell stabilizers, and dual-action agents in ocular allergy: current trends.
Ben-Eli H; Solomon A
Curr Opin Allergy Clin Immunol; 2018 Oct; 18(5):411-416. PubMed ID: 30020258
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the efficacy of olopatadine 0.1% in the treatment of vernal keratoconjunctivitis in terms of clinical improvement based on total ocular symptom score and ocular surface disease index.
Mohan S; Kumar S; Kumar GP; Maheswari A; Bhatia A; Sagar A
Indian J Ophthalmol; 2023 May; 71(5):1822-1827. PubMed ID: 37203036
[TBL] [Abstract][Full Text] [Related]
16. Untargeted Metabolomics Identify a Panel of Urinary Biomarkers for the Diagnosis of Urothelial Carcinoma of the Bladder, as Compared to Urolithiasis with or without Urinary Tract Infection in Dogs.
Tsamouri MM; Durbin-Johnson BP; Culp WTN; Palm CA; Parikh M; Kent MS; Ghosh PM
Metabolites; 2022 Feb; 12(3):. PubMed ID: 35323643
[TBL] [Abstract][Full Text] [Related]
17. Cytokine Storm Syndrome in SARS-CoV-2 Infections: A Functional Role of Mast Cells.
Hafezi B; Chan L; Knapp JP; Karimi N; Alizadeh K; Mehrani Y; Bridle BW; Karimi K
Cells; 2021 Jul; 10(7):. PubMed ID: 34359931
[TBL] [Abstract][Full Text] [Related]
18. The histaminergic control of the iridal vascular tone in rats and its influencing by topical administration of olopatadine and ranitidine.
Luncă DC; Păunescu H; Mușat O; Fulga I
Rom J Ophthalmol; 2019; 63(1):23-28. PubMed ID: 31198894
[No Abstract] [Full Text] [Related]
19. Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: a review of pre-clinical and clinical research.
Rosenwasser LJ; O'Brien T; Weyne J
Curr Med Res Opin; 2005 Sep; 21(9):1377-87. PubMed ID: 16197656
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
